Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BIVI Stock Summary
Top 10 Correlated ETFs
BIVI
In the News
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summer
BioVie Inc (NASDAQ:BIVI) told investors it has secured sufficient funds through a recently completed financing to progress its near-term clinical priority, developing its lead asset NE3107 for Parkinson's disease. It increased its cash balance by approximately $18.8 million after closing an equity financing round last week for gross proceeds of $21 million.
Why Is BioVie (BIVI) Stock Up 100% Today?
BioVie (NASDAQ: BIVI ) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107. NE3107 is BioVie's inhibitor of inflammatory activation of ERK and NFkB.
BioVie shares surge on lead asset NE3107's potential to improve Parkinson's Disease symptoms
BioVie Inc (NASDAQ:BIVI) shares surged 130% in early trade on Friday after the company revealed that its lead asset NE3107 has demonstrated the potential to improve motor and non-motor symptoms in patients with Parkinson's disease in a mid-stage clinical trial. The company said data from its Phase 2a trial showed Parkinson's Disease patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control, while patients in the placebo arm worsened.
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.
Why Is BioVie (BIVI) Stock Down 63% Today?
BioVie (NASDAQ: BIVI ) stock is falling on Wednesday after the company released data from a Phase 3 clinical trial of its Alzheimer's Disease treatment candidate NE3107. Unfortunately for investors in BIVI stock, that study failed to meet its primary endpoint of statistical significance.
BioVie reports efficacy data from NE3107 Phase 3 trial for Alzheimer's Disease
BioVie Inc (NASDAQ:BIVI), the clinical-stage company specializing in drug therapies for neurological disorders, revealed new results from the Phase 3 trial of NE3107 in patients with mild to moderate Alzheimer's Disease (AD). The trial, initiated during the COVID-19 pandemic, enrolled 439 patients across 39 sites.
BioVie: Cautiously Optimistic Ahead Of Phase 3 Alzheimer's Data Unblinding
Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy. Market is significantly undervaluing the probability of a successful data unblinding expected shortly after Thanksgiving. Potential to be the first neurodegenerative biotech to show significant improvement in cognition Alzheimer's disease with suspected disease modification.
BioVie presents positive safety data from Phase 2 liver disease trial
BioVie Inc (NASDAQ:BIVI) has presented data from its Phase 2b trial evaluating the efficacy and safety of its drug candidate BIV201 for liver disease at The American Association for the Study of Liver Diseases – The Liver Meeting in Boston, Massachusetts. The company said the trial showed that BIV201 in combination with the standard of care in patients with refractory ascites due to cirrhosis was well tolerated with no major difference in treatment-emergent adverse events when compared to the standard of care alone.
BIVI Financial details
BIVI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.94 | -4.35 | -10.55 | -0.92 | -1.55 | |
Operating cash flow per share | -0.99 | -0.33 | -0.84 | -0.77 | -1.24 | |
Free cash flow per share | -0.99 | -0.33 | -0.84 | -0.77 | -1.24 | |
Cash per share | 0.13 | 0.01 | 0.36 | 0.76 | 1.04 | |
Book value per share | 0.84 | -4.36 | 0.41 | 0.15 | 0.47 | |
Tangible book value per share | 0.09 | -4.7 | 0.29 | 0.1 | 0.44 | |
Share holders equity per share | 0.84 | -4.36 | 0.41 | 0.15 | 0.47 | |
Interest debt per share | 0 | 1.15 | 0.05 | 0.59 | 0.58 | |
Market cap | 30.16M | 69.01M | 210.23M | 35.76M | 140M | |
Enterprise value | 29.82M | 69.89M | 205.72M | 29.38M | 134.96M | |
P/E ratio | -12.6 | -3.22 | -1.61 | -1.57 | -2.79 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -12.06 | -42.39 | -20.11 | -1.88 | -3.48 | |
PFCF ratio | -12.06 | -42.39 | -20.11 | -1.88 | -3.48 | |
P/B Ratio | 14.15 | -3.21 | 41.63 | 9.74 | 9.13 | |
PTB ratio | 14.15 | -3.21 | 41.63 | 9.74 | 9.13 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -13.16 | -28.37 | -1.49 | -1.09 | -3.05 | |
EV to operating cash flow | -11.92 | -42.92 | -19.68 | -1.55 | -3.35 | |
EV to free cash flow | -11.92 | -42.92 | -19.68 | -1.55 | -3.35 | |
Earnings yield | -0.08 | -0.31 | -0.62 | -0.64 | -0.36 | |
Free cash flow yield | -0.08 | -0.02 | -0.05 | -0.53 | -0.29 | |
Debt to equity | 0 | -0.04 | 0 | 3.34 | 0.94 | |
Debt to assets | 0 | 0.44 | 0 | 0.61 | 0.41 | |
Net debt to EBITDA | 0.15 | -0.35 | 0.03 | 0.24 | 0.11 | |
Current ratio | 1.52 | 0.02 | 4.62 | 4.5 | 2.35 | |
Interest coverage | -9.14K | -0.56 | -246.77 | -12.6 | -10.48 | |
Income quality | 1.02 | 0.1 | 0.08 | 0.73 | 0.8 | |
Dividend Yield | 0 | 0.25 | 0 | 0 | 0 | |
Payout ratio | -0.02 | -0.8 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.74 | 0.8 | 0.24 | 0.06 | 0.03 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.22 | 20.66 | 9.83 | 1.76 | 4.05 | |
ROIC | -1.15 | 0.17 | -27.45 | -1.48 | -1.64 | |
Return on tangible assets | -3.55 | -51.94 | -28.4 | -1.21 | -1.47 | |
Graham Net | -0.04 | -4.78 | 0.28 | 0.09 | 0.44 | |
Working capital | 230.59K | -23.11M | 3.61M | 14.61M | 19.55M | |
Tangible asset value | 230.59K | -23.17M | 3.61M | 2.46M | 14.36M | |
Net current asset value | 230.59K | -23.17M | 3.61M | 2.34M | 14.28M | |
Invested capital | 0 | -0.04 | 0 | 3.34 | 0.94 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 663.84K | 851.34K | 1.13M | 499.41K | 2.96K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 705.69 | 2K | 1.59K | 3.76 | 4.76 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.52 | 0.18 | 0.23 | 97.19 | 76.76 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.12 | 1 | -25.9 | -6.21 | -3.28 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.61 | -0.43 | -0.25 | -0.29 | -0.22 | |
Operating cash flow per share | -0.26 | -0.33 | -0.31 | -0.33 | -0.15 | |
Free cash flow per share | -0.26 | -0.33 | -0.31 | -0.33 | -0.15 | |
Cash per share | 1.47 | 1.24 | 0.94 | 0.58 | 0.53 | |
Book value per share | 0.84 | 0.61 | 0.42 | 0.21 | 0.2 | |
Tangible book value per share | 0.8 | 0.59 | 0.4 | 0.18 | 0.17 | |
Share holders equity per share | 0.84 | 0.61 | 0.42 | 0.21 | 0.2 | |
Interest debt per share | 0.46 | 0.42 | 0.43 | 0.36 | 0.29 | |
Market cap | 242.18M | 285.43M | 156.37M | 125.29M | 48.1M | |
Enterprise value | 209.8M | 268.05M | 151.33M | 116.46M | 38.13M | |
P/E ratio | -3.2 | -4.69 | -4.29 | -2.92 | -1.43 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -30.24 | -24.32 | -13.85 | -10.29 | -8.14 | |
PFCF ratio | -30.24 | -24.32 | -13.85 | -10.29 | -8.14 | |
P/B Ratio | 9.29 | 13.14 | 10.19 | 16.6 | 6.42 | |
PTB ratio | 9.29 | 13.14 | 10.19 | 16.6 | 6.42 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -18.49 | -19.8 | -14.19 | -11.25 | -4.48 | |
EV to operating cash flow | -26.2 | -22.84 | -13.41 | -9.56 | -6.45 | |
EV to free cash flow | -26.2 | -22.84 | -13.41 | -9.56 | -6.45 | |
Earnings yield | -0.08 | -0.05 | -0.06 | -0.09 | -0.17 | |
Free cash flow yield | -0.03 | -0.04 | -0.07 | -0.1 | -0.12 | |
Debt to equity | 0.51 | 0.64 | 0.94 | 1.64 | 1.37 | |
Debt to assets | 0.28 | 0.31 | 0.41 | 0.52 | 0.48 | |
Net debt to EBITDA | 2.85 | 1.28 | 0.47 | 0.85 | 1.17 | |
Current ratio | 5.9 | 2.75 | 2.35 | 1.72 | 1.47 | |
Interest coverage | -10.91 | -12.72 | -9.91 | -10.83 | -10.7 | |
Income quality | 0.51 | 0.78 | 1.24 | 1.14 | 0.7 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.38 | 2.44 | 1.55 | 1.16 | 0.99 | |
ROIC | -0.35 | -0.39 | -0.41 | -0.59 | -0.54 | |
Return on tangible assets | -0.41 | -0.34 | -0.27 | -0.47 | -0.41 | |
Graham Net | 0.79 | 0.58 | 0.39 | 0.14 | 0.16 | |
Working capital | 38.19M | 28.04M | 19.55M | 9.55M | 6.58M | |
Tangible asset value | 24.97M | 20.68M | 14.36M | 6.62M | 6.62M | |
Net current asset value | 24.87M | 20.58M | 14.28M | 6.55M | 6.56M | |
Invested capital | 0.51 | 0.64 | 0.94 | 1.64 | 1.37 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.62M | 1.63M | 4.16K | 3.1K | 1.36K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 4.39K | 6.52 | 4.66 | 3.63 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.02 | 13.81 | 19.3 | 24.82 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.73 | -0.7 | -0.59 | -1.42 | -1.12 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BIVI Frequently Asked Questions
What is BioVie Inc. stock symbol ?
BioVie Inc. is a US stock , located in Carson city of Nv and trading under the symbol BIVI
What is BioVie Inc. stock quote today ?
BioVie Inc. stock price is $0.5302 today.
Is BioVie Inc. stock public?
Yes, BioVie Inc. is a publicly traded company.